5000 Alzheimer's patients monitored for brain swelling risks on new drug
NCT ID NCT06322667
First seen Feb 01, 2026 · Last updated May 09, 2026 · Updated 9 times
Summary
This study tracks 5000 people with early Alzheimer's who are taking lecanemab in regular medical care. Researchers want to see how often brain imaging abnormalities (ARIA) occur and how doctors manage treatment when they do. The goal is to better understand the real-world safety of this medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Eisai trial site 1
RECRUITINGTokyo, Japan
-
Eisai trial site 2
RECRUITINGHiroshima, Japan
-
Eisai trial site 3
RECRUITINGKyoto, Japan
Conditions
Explore the condition pages connected to this study.